Mucopolysaccharidosis VII Disease Monitoring Program
← catalyst calendarNCT03604835 · readout ≤ 2,081 d
Sponsored by Ultragenyx Pharmaceutical Inc (industry) · RARE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
50estimated
Sites
14
Countries
Argentina, Brazil, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-01-29 | actual | When the study began enrolling |
| Primary completion | Apr 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2018-07-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mucopolysaccharidosis VII
- MPS VII
- MPS 7
- Sly Syndrome
Intervention
- Other: No Intervention
Primary outcomes
what the primary-completion date above is the date OFClinical Course of MPS VII Disease
measured 10 years
Long-term Effectiveness of Vestronidase Alfa
measured 10 years
Long-term Safety of Vestronidase Alfa
measured 10 years
Permalink · RARE's whole pipeline · Catalyst calendar · Every registered study · What changed